INT96850

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 42
Total Number 42
Disease Relevance 24.89
Pain Relevance 12.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CCL2) extracellular space (CCL2) aging (CCL2)
extracellular region (CCL2) cell adhesion (CCL2) cytoskeleton organization (CCL2)
Anatomy Link Frequency
monocyte 3
stellate cells 2
HCEC 2
osteoblasts 2
astrocytes 2
CCL2 (Homo sapiens)
Pain Link Frequency Relevance Heat
chemokine 227 100.00 Very High Very High Very High
ischemia 26 100.00 Very High Very High Very High
Inflammatory marker 4 100.00 Very High Very High Very High
cytokine 225 99.96 Very High Very High Very High
Inflammation 301 99.76 Very High Very High Very High
Chronic pancreatitis 95 99.64 Very High Very High Very High
Morphine 55 99.60 Very High Very High Very High
Arthritis 125 99.42 Very High Very High Very High
Cannabinoid 52 99.12 Very High Very High Very High
Endocannabinoid 48 98.52 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 349 100.00 Very High Very High Very High
Nephritis 34 100.00 Very High Very High Very High
Cv Unclassified Under Development 23 100.00 Very High Very High Very High
Injury 29 99.96 Very High Very High Very High
Systemic Lupus Erythematosus 242 99.84 Very High Very High Very High
Acute Coronary Syndrome 20 99.72 Very High Very High Very High
Pancreatitis 97 99.64 Very High Very High Very High
Renal Disease 235 99.54 Very High Very High Very High
Arthritis 142 99.42 Very High Very High Very High
Diabetes Mellitus 38 99.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, the lower maternal and fetal MCP-1 concentrations in our IUGR cohort may indicate failure of trophoblast invasion, suggesting that downregulation of MCP-1 may be involved in the pathogenesis of IUGR.
Negative_regulation (downregulation) of MCP-1
1) Confidence 0.59 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0.36 Pain Relevance 0
A consistent decrease in interleukin-6 and CCL2 level was seen compared with pretreatment values in serial blood samples (days 1, 7, 28, 56, and 84).
Negative_regulation (decrease) of CCL2 in blood
2) Confidence 0.57 Published 2004 Journal Clin. Cancer Res. Section Body Doc Link 15475440 Disease Relevance 0.11 Pain Relevance 0
Maternal and fetal MCP-1 concentrations were significantly decreased in
Negative_regulation (decreased) of MCP-1
3) Confidence 0.43 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0 Pain Relevance 0.05
suggesting that downregulation of MCP-1 may be involved in the pathogenesis of
Negative_regulation (downregulation) of MCP-1
4) Confidence 0.43 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0 Pain Relevance 0.04
Reduced maternal and fetal MCP-1

concentrations in IUGR may reflect failure of trophoblast invasion, suggesting that down-regulation of MCP-1 may be involved in the pathogenesis of IUGR.

Negative_regulation (regulation) of MCP-1
5) Confidence 0.43 Published 2007 Journal Mediators of Inflammation Section Abstract Doc Link PMC2234089 Disease Relevance 0 Pain Relevance 0
Furthermore, treatment of human astrocytes with morphine has been shown by others to downregulate CCL2 mRNA and protein expression [6].
Negative_regulation (downregulate) of CCL2 mRNA in astrocytes associated with morphine
6) Confidence 0.43 Published 2006 Journal J Neuroinflammation Section Body Doc Link PMC1712222 Disease Relevance 0.09 Pain Relevance 1.28
In our recent study, a daily per oral administration of GTE (200 mg/kg) modestly ameliorated rat adjuvant-induced arthritis, which was accompanied by a decrease in MCP-1/CCL2 and GRO?
Negative_regulation (decrease) of CCL2 associated with arthritis
7) Confidence 0.41 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888220 Disease Relevance 1.11 Pain Relevance 0.60
In our recent study, a daily per oral administration of GTE (200 mg/kg) modestly ameliorated rat adjuvant-induced arthritis, which was accompanied by a decrease in MCP-1/CCL2 and GRO?
Negative_regulation (decrease) of MCP-1 associated with arthritis
8) Confidence 0.41 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888220 Disease Relevance 1.11 Pain Relevance 0.60
Based on the results of CoPub Discovery, it might be hypothesized that pitavastatin might prevent foam cell formation by blocking monocyte differentiation via suppression of CCL2 and PPAR?
Negative_regulation (suppression) of CCL2 in foam cell
9) Confidence 0.40 Published 2010 Journal PLoS Computational Biology Section Body Doc Link PMC2944780 Disease Relevance 0.67 Pain Relevance 0
Maternal and fetal MCP-1

concentrations were decreased (P<001 and P = .018, resp.), whereas N1 MCP-1 concentrations were elevated in IUGR group (P = .012).

Negative_regulation (decreased) of MCP-1
10) Confidence 0.38 Published 2007 Journal Mediators of Inflammation Section Abstract Doc Link PMC2234089 Disease Relevance 0 Pain Relevance 0
In conclusion, the reduced maternal and fetal MCP-1
Negative_regulation (reduced) of MCP-1
11) Confidence 0.38 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0 Pain Relevance 0.03
After peaking at day 7 after injury, MCP-1 levels began to decline rapidly and had returned to baseline by day 150.
Negative_regulation (decline) of MCP-1 associated with injury
12) Confidence 0.37 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 16524371 Disease Relevance 0.75 Pain Relevance 0.63
The DeltaMCP-1 (between 6 months and baseline) was significantly related only to the lumen loss (r=0.443, p=0.023), which suggests that the reduction of MCP-1 is the best contributor to decreased lumen loss.
Negative_regulation (reduction) of MCP-1 in lumen
13) Confidence 0.36 Published 2008 Journal Intern. Med. Section Body Doc Link 18175998 Disease Relevance 0.06 Pain Relevance 0
Using in vivo testing conducted in mouse CIA model, another study showed that EGCG (20 mg/kg, intraperitoneally daily) ameliorated arthritis and macrophage infiltration, and caused a reduction in the amount of MCP-1/CCL2-synthesizing osteoblasts [31].


Negative_regulation (reduction) of CCL2 in osteoblasts associated with arthritis
14) Confidence 0.30 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888220 Disease Relevance 1.71 Pain Relevance 0.64
Using in vivo testing conducted in mouse CIA model, another study showed that EGCG (20 mg/kg, intraperitoneally daily) ameliorated arthritis and macrophage infiltration, and caused a reduction in the amount of MCP-1/CCL2-synthesizing osteoblasts [31].


Negative_regulation (reduction) of MCP-1 in osteoblasts associated with arthritis
15) Confidence 0.30 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888220 Disease Relevance 1.71 Pain Relevance 0.64
As observed above, ICAM-1, IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was reduced by the IKK inhibitors.
Negative_regulation (reduced) of MCP-1
16) Confidence 0.30 Published 2006 Journal Mol. Pharmacol. Section Abstract Doc Link 16687566 Disease Relevance 0.42 Pain Relevance 0.41
In addition, we reported that levels of MCP-1/CCL2 decreased after immunosuppressive treatment.
Negative_regulation (decreased) of CCL2
17) Confidence 0.27 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2896663 Disease Relevance 0.24 Pain Relevance 0.39
RESULTS: Unstimulated cells released low amounts of MCP-1, IL-6 and SCF.
Negative_regulation (amounts) of MCP-1
18) Confidence 0.27 Published 2006 Journal J. Urol. Section Body Doc Link 16407046 Disease Relevance 0.17 Pain Relevance 0
The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor.
Negative_regulation (supporessed) of MCP-1
19) Confidence 0.23 Published 2003 Journal Exp. Eye Res. Section Abstract Doc Link 12697421 Disease Relevance 0.15 Pain Relevance 0.29
reverse, 5'-TCTCGGAGCTCAGGATCACA-3' (NM_020529); ICAM-1 forward, 5'-GGTGACCGTGAATGTGCTC-3'; ICAM-1 reverse, 5'-GCCTGCAGTGCCCATTATG-3' (NM_000201.2); Mcp-1 forward 5'-CGCTCAGCCAGATGCAATC-3'; Mcp-1 reverse, 5'-GCACTGAGATCTTCCTATTGGTGAA-3' (NM_02982); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward 5'-GGAGTCAACGGATTTGGTCGTA-3'; GAPDH reverse, 5'-GGCAACAATATCCACTTTACCAGAGT-3' (NM_02046).
Negative_regulation (reverse) of Mcp-1
20) Confidence 0.23 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875647 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox